Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Sep;186(5):e117-e121.
doi: 10.1111/bjh.15946. Epub 2019 May 15.

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

Maria-Victoria Mateos  1 , Robert Z Orlowski  2 , Enrique M Ocio  3 , Paula Rodríguez-Otero  4 , Donna Reece  5 , Philippe Moreau  6 , Nikhil Munshi  7 , David E Avigan  8 , David S Siegel  9 , Razi Ghori  10 , Mohammed Z H Farooqui  10 , Patricia Marinello  10 , Jesus San-Miguel  4
Affiliations
Clinical Trial

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

Maria-Victoria Mateos et al. Br J Haematol. 2019 Sep.
No abstract available

Keywords: dexamethasone; lenalidomide; multiple myeloma; pembrolizumab; relapsed/refractory.

PubMed Disclaimer

References

REFERENCES

    1. Ahamadi, M., Freshwater, T., Prohn, M., Li, C.H., De Alwis, D.P., de Greef, R., Elassaiss-Schaap, J., Kondic, A. & Stone, J.A. (2016) Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT: Pharmacometrics & Systems Pharmacology, 6, 49-57.
    1. The ASCO Post (2017) FDA places clinical hold on three studies evaluating pembrolizumab in multiple myeloma. http://www.ascopost.com/News/57813. Accessed 5 February 2019.
    1. Badros, A., Hyjek, E., Ma, N., Lesokhin, A., Dogan, A., Rapoport, A.P., Kocoglu, M., Lederer, E., Philip, S., Milliron, T., Dell, C., Goloubeva, O. & Singh, Z. (2017) Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma. Blood, 130, 1189-1197.
    1. Durie, B.G.M., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V.; on behalf of the International Myeloma Working Group. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
    1. Gorgun, G., Samur, M.K., Cowens, K.B., Paula, S., Bianchi, G., Anderson, J.E., White, R.E., Singh, A., Ohguchi, H., Suzuki, R., Kikuchi, S., Harada, T., Hideshima, T., Tai, Y.T., Laubach, J.P., Raje, N., Magrangeas, F., Minvielle, S., Avet-Loiseau, H., Munshi, N.C., Dorfman, D.M., Richardson, P.G. & Anderson, K.C. (2015) Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clinical Cancer Research, 21, 4607-4618.